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emerged as a major complication of bortezomib therapy, which usu-
ally appears in the first courses of therapy with a number of sensory 
and painful symptoms, including reduced threshold to mechanical 
and cold stimuli. No satisfactory explanation or effective treatment 
exists for bortezomib-evoked CIPN.
Patients (or Materials) and Methods: In this study, we evaluated 
whether TRPA1 acted as a critical mediator of CIPN by bortezomib 
or oxaliplatin in a mouse model system.
Results: Our data demonstrated that CIPN hypersensitivity pheno-
type that was stably established by bortezomib could be transiently 
reverted by systemic or local treatment with the TRPA1 antagonist 
HC-030031. A similar effect was produced by the oxidative stress 
scavenger α -lipoic acid. Notably, the CIPN phenotype was abolished 
completely in mice that were genetically deficient in TRPA1, high-
lighting its essential role. Administration of bortezomib or oxalipl-
atin, which also elicits TRPA1-dependent hypersensitivity, produced 
a rapid, transient increase in plasma of carboxy-methyllysine, a by-
product of oxidative stress. Short-term systemic treatment with either 
HC-030031 or α -lipoic acid could completely prevent hypersensitiv-
ity if administered before the cytotoxic drug.
Conclusion: Our findings highlight a key role for early activation/
sensitization of TRPA1 by oxidative stress by-products in producing 
CIPN. Furthermore, they suggest prevention strategies for CIPN in 
patients through the use of early, short-term treatments with TRPA1 
antagonists.
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Introduction: Tanacetum parthenium L. (feverfew) has long been 
known as a migraine remedy and, according to positive results of 
clinical trials, it is currently recommended for migraine prevention. 
However, the mechanism responsible for such protective action 
remains unknown. Parthenolide, a major ingredient of feverfew, is 
a reactive molecule that can interact with nucleophilic sites of tran-
sient receptor potential ankyrin 1 (TRPA1). Thus, we hypothesized 
that parthenolide inhibits TRPA1 channel on peptidergic trigeminal 
nerves.
Patients (or Materials) and Methods: Experiments were performed 
in vitro in human and mouse cultured cells/neurons and rat isolated 
tissues, and in in vivo in rats and wild-type and TRPA1-deficient 
mice. Electrophysiologic, calcium, neuropeptide release, smooth 
muscle motility, allodynic and nociceptive responses, and changes in 
meningeal blood flow were evaluated.
Results: Parthenolide selectively activates recombinant (trans-
fected cells) or natively expressed (rat/mouse trigeminal neurons) 
TRPA1, and, by targeting TRPA1, activates trigeminal nerve end-
ings. However, parthenolide behaves as a partial agonist at neuronal 
TRPA1 of the rat urinary bladder, desensitizes the recombinant 
TRPA1, and, after initial stimulation, renders peptidergic, TRPA1-
expressing nerve terminals unresponsive to any stimulus. These 
effects causes abrogation of nociceptive responses evoked by TRPA1 
agonists, and inhibition of calcitonin gene-related peptide (CGRP) 
release from trigeminal neurons, and, in particular, of CGRP-mediated 
meningeal vasodilatation evoked by TRPA1 stimulants and other 
mechanisms.
Conclusion: Peculiar features of parthenolide (TRPA1 partial ago-
nism, channel desensitization, and defunctionalisation of peptidergic 
primary sensory neurons), ultimately resulting in the inhibition of 
CGRP release from trigeminal neurons, may contribute to the anti-
migraine effect of feverfew.
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Introduction: Facilitation of spinal GABAergic inhibition with 
benzodiazepines (BZD) reverses pain sensitization in rodents. 
In human, the use of BZD in pain is limited by their sedative 
effect. We previously demonstrated the antihyperalgesic effect of 
clobazam, a 1,5-BZD, in mice and its lack of sedation at effective 
doses. Hence we designed a pharmacokinetic-pharmacodynamic 
study to explore the effect of antihyperalgesic effect of BZD in 
healthy volunteers.
Patients (or Materials) and Methods: Randomized, double-blind, 
crossover controlled study in 25 healthy volunteers comparing 
clobazam 20 mg with clonazepam 1 mg (positive control) and 
tolterodine 1.37 mg (active placebo) 2 weeks apart. The primary 
outcome was the effect on the size of secondary hyperalgesia elicited 
by the UVB irradiation of the skin of the forearm (sunburn model). 
Quantitative sensory testing, nociceptive flexion reflex, and the cold 
pressor test were also performed. Sedation was measured by a visual 
analog scale (VAS), the digit substitution symbol test (DSST), and 
saccadic eye movements (SEM) recording. Blood samples were taken 
to determine the pharmacokinetic of clobazam.
Results: We observed a reduction of the area of the secondary 
hyperalgesia with clobazam and clonazepam. The maximum of the 
effect was seen at t = 2 hours (median of the difference between t 
= 2 and baseline [MOD2-0] [+/-CI] vs placebo: 19.2 cm2 (–2.7-
37.9) P = 0.07 for clobazam and 29.6 cm2 (2.0-55.1), P = 0.03, 
for clonazepam), in line with the expected Tmax of the compounds. 
Regarding sedation, at t = 2 hours, we saw an effect of the 2 active 
compounds on the VAS (MOD2-0 [+/-CI] vs placebo: 14 mm (1.0-
21.5), P = 0.03 for clobazam and 26 mm (14.0-37.5), P < 0.001 
for clonazepam) and on the peak velocity of the SEM (MOD2-0 
[+/-CI] vs placebo: 30.8 deg./s. (6.6-60.6), P < 0.01 for clobazam 
and 55.2 deg./s.(24.5–85.0), P < 0.01 for clonazepam]. The DSST 
was only impaired by clonazepam (MOD2-0 [+/-CI] vs placebo: 
11.0 (5.0–18.0), P = 0.03). These effects disappeared at t = 8 hours 
except that clonazepam still impaired SEM (median of the differ-
ence between t = 8 and baseline [+/-CI] vs placebo: 28.3 deg./s. 
(5.3–52.7), P = 0.01).
Conclusion: Clobazam and clonazepam decreased the area of sec-
ondary hyperalgesia in the sunburn model, which suggests that 
GABAA receptor ligands are involved in the modulation of pain 
sensitization in human. Clobazam was less sedative than clonaz-
epam and therefore a suitable “tool compound” to assess the role of 
GABAergic pathways in human.
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